Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction - Observations from the TIMI 14 trial

Article

关键词: LEFT-VENTRICULAR FUNCTION;    SEGMENT ELEVATION;    CONTRAST ECHOCARDIOGRAPHY;    SUCCESSFUL THROMBOLYSIS;    DIRECT ANGIOPLASTY;    ENDOTHELIAL-CELLS;    STRONG PREDICTOR;    SHORT-TERM;    RECOVERY;    RESOLUTION;   

DOI  :  10.1161/01.CIR.101.3.239

来源: SCIE

【 摘 要 】

Background-In the presence of ST-elevation myocardial infarction, patients with successful epicardial reperfusion (TIMI 3 flow) but persistent ST elevation on a 12-lead ECG are at high risk for subsequent death and left ventricular dysfunction. In the TIMI 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA enhanced the speed and efficacy of epicardial reperfusion. We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation. Methods and Results-All 346 patients with interpretable baseline and 90-minute ECGs, treated with either tPA alone or abciximab plus reduced-dose tPA (combination therapy), were included. Patients receiving combination therapy (n=221) had a 59% rate of complete (greater than or equal to 70%) ST resolution at 90 minutes versus 37% in those treated with tPA alone (n=125) (P<0.0001). When the analysis was limited to patients with TIMI 3 flow, patients treated with combination therapy (n=151) remained significantly more likely to achieve complete ST resolution than those receiving tPA alone (n=80) (69% versus 44%; P=0.0002). Conclusions-Combination therapy with abciximab and reduced-dose tPA improves myocardial (microvascular) reperfusion, as reflected in greater ST-segment resolution, in addition to epicardial flow. This finding may translate into improved clinical outcomes by enhancing myocardial salvage.

【 授权许可】

Free